Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Therapeutic cervical cancer vaccine eradicates established tumors in mice

Feb. 7, 2013

Health Canada grants approval to Adcetris for two lymphoma indications

Feb. 4, 2013

Teva Pharmaceutical terminates agreements with CureTech

Feb. 4, 2013

Targovax includes first patient in phase I/II TG-01 study

Feb. 1, 2013

New MAbs described by Oxford BioTherapeutics

Feb. 1, 2013

Encouraging results from phase III study of obinutuzumab in CLL

Jan. 31, 2013

FDA clears IND application for ICT-140

Jan. 30, 2013

OncoPep begins phase I/IIa trial of multipeptide vaccine in smoldering multiple myeloma

Jan. 30, 2013

Algeta begins research program on epratuzumab-based targeted thorium conjugate

Jan. 30, 2013

Chugai seeks Japanese approval of trastuzumab emtansine

Jan. 29, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 14, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026